Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.83 |
| ▸ | USP2 | O75604 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | HPGD | P15428 | 2/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | AQP1 | P29972 | 1/20 | 0.37 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.37 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piretanide SCHEMBL49473 | 0.91 | KDM4E (1.00) | LMNAKDM4EHSD17B10USP2ALDH1A1 | |
| Piretanide SCHEMBL1741994 | 0.91 | KDM4E (1.00) | LMNAKDM4EHSD17B10USP2ALDH1A1 | |
| Piretanide SCHEMBL30230376 | 0.91 | KDM4E (1.00) | LMNAKDM4EHSD17B10USP2ALDH1A1 | |
| SCHEMBL230212 | 0.90 | ALDH1A1 (0.78) | LMNAKDM4EHSD17B10USP2ALDH1A1 | |
| SCHEMBL231996 | 0.90 | ALDH1A1 (0.85) | LMNAKDM4EHSD17B10USP2ALDH1A1 | |
| SCHEMBL2741891 | 0.90 | KDM4E (0.98) | LMNAKDM4EHSD17B10USP2ALDH1A1 | |
| Piretanide SCHEMBL9837127 | 0.90 | KDM4E (0.98) | LMNAKDM4EHSD17B10USP2ALDH1A1 | |
| SCHEMBL16581077 | 0.89 | ALDH1A1 (0.83) | LMNAKDM4EHSD17B10USP2ALDH1A1 | |
| Piretanide SCHEMBL7895002 | 0.89 | KDM4E (0.95) | LMNAKDM4EHSD17B10USP2ALDH1A1 | |
| Piretanide SCHEMBL18075706 | 0.89 | KDM4E (0.95) | LMNAKDM4EHSD17B10USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-1951702-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1937242-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | NEUROTHERAPEUTICS PHARMA, L.L.C. | 2007-06-28 | — | — | US | disclosed |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | NEUROTHERAPEUTICS PHARMA, L.L.C. | 2007-06-28 | — | — | US | disclosed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | LMNA 4006/4885KDM4E 2426/4885HSD17B10 1162/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | LMNA 3992/4885KDM4E 2228/4885HSD17B10 1264/4885 |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | LMNA 4006/4885KDM4E 2426/4885HSD17B10 1162/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | LMNA 4297/4885KDM4E 2764/4885HSD17B10 957/4885 |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | AQP4, AVPR2, AQP1 | LMNA 3676/4885KDM4E 3557/4885HSD17B10 357/4885 |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | SLC6A2, SLC1A2, SLC18A2 | LMNA 4437/4885KDM4E 1504/4885HSD17B10 1934/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | LMNA 3842/4885KDM4E 3717/4885HSD17B10 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.